The effect of ozone treatment on serum markers in patients with fatty liver disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-11001273

Enrollment

Unknown

Registered

2011-04-06

Start date

2009-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver disease

Interventions

Tota:Foundation treatment is same. Patients in the treatment group received ozone treatment, while the patients in the control group did not receive any antioxidant treatment.

Eligibility

Sex/Gender

All

Age

22 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with confirmed steatosis in liver were included in the study; steatosis was confirmed according to the 2006 guidelines; 2. No contraindications to ozone treatment.

Exclusion criteria

Exclusion criteria: We excluded patients with viral hepatitis (hepatitis B virus, hepatitis C virus, and cytomegalovirus), toxic, autoimmune, and metabolic liver diseases (Wilson's disease, alpha 1-antitrypsin deficiency, and cystic fibrosis), cirrhosis, alcoholic liver diseases, cancer, vascular liver diseases, and hypothyroidism-related steatosis.

Design outcomes

Primary

Measure	Time frame
The serum of leptin, high-sensitivity C-reactive protein (hs-crp), interleukin-6 (IL-6), oxidized low density Lipid, NO, F2a;	—

Countries

China

Contacts

Public ContactFangping He

hefp@sina.com+86 09914366305, 13999801966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026